Access
This article is part of Nature's premium content.
Published online 22 April 2009 | Nature 458, 951 (2009) | doi:10.1038/458951a
News
Fees delay pharmed drug
European trial of 'pharmed' anti-HIV monoclonal delayed by costly regulatory process.
Human tests of a potent antibody against HIV have been delayed by up to a year because of wrangling over the application to run a clinical trial in Europe, Nature has learned.
The consortium behind the project, which uses genetically modified (GM) tobacco plants to make the monoclonal antibody 2G12, now hopes to make its application in June.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
